5.11
0.58%
-0.03
アフターアワーズ:
5.11
前日終値:
$5.14
開ける:
$5.09
24時間の取引高:
175.78K
Relative Volume:
0.43
時価総額:
$109.01M
収益:
$73.62M
当期純損益:
$-138.24M
株価収益率:
-0.779
EPS:
-6.56
ネットキャッシュフロー:
$-99.19M
1週間 パフォーマンス:
-7.59%
1か月 パフォーマンス:
-11.13%
6か月 パフォーマンス:
-65.38%
1年 パフォーマンス:
-57.94%
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
500 ARSENAL STREET, WATERTOWN, MA
ENTA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.11 | 109.01M | 73.62M | -138.24M | -99.19M | -6.56 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
2022-12-09 | 開始されました | H.C. Wainwright | Buy |
2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
2020-11-24 | 開始されました | Evercore ISI | Underperform |
2020-08-28 | 再開されました | ROTH Capital | Buy |
2020-08-26 | 開始されました | Piper Sandler | Overweight |
2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-05-24 | 開始されました | Wolfe Research | Outperform |
2019-04-23 | アップグレード | Berenberg | Hold → Buy |
2018-12-13 | 開始されました | Berenberg | Hold |
2018-06-06 | 開始されました | ROTH Capital | Buy |
2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 繰り返されました | Barclays | Underweight |
2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enanta Pharmaceuticals (ENTA) Projected to Post Earnings on Wednesday - MarketBeat
Petri Dish: A monthly Alzheimer's drug from Biogen; Watertown biotech CEO pay falls 66% - The Business Journals
Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Assenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Assenagon Asset Management S.A. Buys 49,050 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last? - Yahoo Finance
JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages - MarketBeat
Enanta stock hits 52-week low at $4.83 amid market challenges - Investing.com Australia
Enanta stock hits 52-week low at $4.83 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
ENTA (Enanta Pharmaceuticals) Peter Lynch Fair Value : N/A (As of Jan. 11, 2025) - GuruFocus.com
Enanta stock hits 52-week low at $5.29 amid market challenges - Investing.com Nigeria
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
(ENTA) Technical Pivots with Risk Controls - Stock Traders Daily
Enanta stock touches 52-week low at $5.68 amid market challenges - Investing.com Australia
Enanta stock touches 52-week low at $5.68 amid market challenges By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for ENTA Q1 Earnings - Defense World
Equities Analysts Offer Predictions for ENTA Q1 Earnings - MarketBeat
Paxlovid Survives Patent Dispute, Securing Pfizer’s Exclusive Rights - The Africa Logistics
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
FY2029 Earnings Estimate for ENTA Issued By HC Wainwright - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Equities Analysts Set Expectations for ENTA FY2029 Earnings - MarketBeat
Pfizer prevails in Enanta patent case over Covid-19 drug By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals stock remains Buy-rated with Phase 2 data driving model revisions - Investing.com Australia
When (ENTA) Moves Investors should Listen - Stock Traders Daily
Pfizer prevails in Enanta patent case over Covid-19 drug - Investing.com India
Pfizer Gets Enanta Patent Voided in Case Over Paxlovid Royalties - Bloomberg Law
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dis - GuruFocus.com
HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00 - MarketBeat
Enanta to appeal as Pfizer wins Paxlovid patent ruling - MSN
Enanta stock slips as Pfizer wins Paxlovid patent (PFE:NYSE) - Seeking Alpha
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer - MarketWatch
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling - StockTitan
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):